← All trials
NCT04326764
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 24, 2018
- Primary completion
- Jul 31, 2023
- Completion date
- Oct 31, 2023
- First posted
- Mar 30, 2020
- Last posted
- Mar 30, 2020
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- J. W. Goethe UniversityLead sponsor
- J. W. Goethe UniversityReponsible party - principal investigator
- J. W. Goethe UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.